EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

ORAL COMMUNICATION | Outcomes of direct oral anticoagulants in unusual-site thrombosis: impact of active cancer

S. Guglielmo, M. Lovisotto, L. Scarano, E. De Bon, S. Barbar

Italian Journal of Medicine · 22.05.2026 · 20 (s1)

DOI: 10.4081/itjm.2026.2592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Italian Journal of Medicine, online erschienen am 22.05.2026. Verfasst von S. Guglielmo und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Splanchnic vein thrombosis (SVT) and cerebral venous thrombosis (CVT) are unusual sites of thrombosis. Cancer is a common predisposing factor and is associated with worse outcomes and increased bleeding risk. Evidence supporting the use of direct oral anticoagulants (DOACs), especially in patients with active malignancy, is limited. Materials and Methods. This single-center longitudinal observational study included adult patients with imaging-confirmed SVT or CVT treated with DOACs between January 2018 and October 2025. Inclusion was retrospective with prospective follow-up. Primary outcomes were radiological recanalization and thrombotic recurrence. Secondary outcomes included major bleeding, clinically relevant non-major bleeding (CRNMB), and all-cause mortality.

Results

43 patients were included (median age 58 years; 46.5% male), 26 with SVT and 17 with CVT; 16 had active cancer. Median follow-up was 17 months. Recanalization was assessable in 41 patients and was complete in 43.9%, partial in 29.3%, and absent in 26.8%. Active cancer was associated with a lower likelihood and longer time to recanalization. Two thrombotic recurrences (4.7%) occurred. Clinically relevant bleeding was observed in 16.3%, including 7.0% major bleeding. Seven deaths occurred, all in patients with active cancer.

Conclusions

In this cohort of SVT and CVT treated with DOACs, recurrence and bleeding rates were acceptable. Active cancer identified a high-risk subgroup with reduced recanalization and increased mortality, supporting tailored management strategies.

Zitieren

APA

Guglielmo, S., Lovisotto, M., Scarano, L., Bon, E. D., & Barbar, S. (2026). ORAL COMMUNICATION | Outcomes of direct oral anticoagulants in unusual-site thrombosis: impact of active cancer. Italian Journal of Medicine, 20(s1). https://doi.org/10.4081/itjm.2026.2592

Vancouver

Guglielmo S, Lovisotto M, Scarano L, Bon ED, Barbar S. ORAL COMMUNICATION | Outcomes of direct oral anticoagulants in unusual-site thrombosis: impact of active cancer. Italian Journal of Medicine. 2026;20(s1). doi:10.4081/itjm.2026.2592

BibTeX
@article{Guglielmo2026,
  author = {Guglielmo, S. and Lovisotto, M. and Scarano, L. and Bon, E. De and Barbar, S.},
  title = {ORAL COMMUNICATION | Outcomes of direct oral anticoagulants in unusual-site thrombosis: impact of active cancer},
  journal = {Italian Journal of Medicine},
  year = {2026},
  volume = {20},
  number = {s1},
  doi = {10.4081/itjm.2026.2592}
}
Kostenlos starten →